SK pharmteco invests US$ 260 million to expand global small molecule, peptide production
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Developed in consultation with clinicians and patients for an enhanced user experience
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
NMC to continue its efforts to improve and enhance the quality of medical education in the country
Subscribe To Our Newsletter & Stay Updated